AgingResearch.NewsJoin free

Metformin + sulphonylurea

Intervention

1 paper1 finding

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab
  • Human trial1

Associations

1

Diabetes-related death

no changein humans1

1 study

  1. Metformin + sulphonylurea is associated with diabetes-related death in humans (5% risk reduction (95% CI −33 to 32); p=0.78).

    “did not show an increased risk in diabetes-related death in patients treated with a combination of sulphonylurea and metformin (risk reduction 5% [-33 to 32], p=0.78).”

    HumansEpidemiological assessment of concurrent sulphonylurea and metformin therapyn = 4,416

    Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

    Lancet (London, England)12 Sep 1998

Latest

Related